Insulet (PODD) Competitors

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Does the media favor BDX or PODD?

In the previous week, Becton, Dickinson and Company had 11 more articles in the media than Insulet. MarketBeat recorded 39 mentions for Becton, Dickinson and Company and 28 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.30 beat Insulet's score of 0.84 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	30 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	17 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Is BDX or PODD more profitable?

Insulet has a net margin of 20.19% compared to Becton, Dickinson and Company's net margin of 8.47%. Insulet's return on equity of 24.46% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	8.47%	15.74%	7.29%
Insulet	20.19%	24.46%	8.33%

Which has preferable valuation and earnings, BDX or PODD?

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$20.64B	3.19	$1.71B	$6.02	38.06
Insulet	$2.07B	9.29	$206.30M	$5.79	47.33

Does the MarketBeat Community favor BDX or PODD?

Insulet received 134 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 66.40% of users gave Insulet an outperform vote while only 62.41% of users gave Becton, Dickinson and Company an outperform vote.

Company	Underperform	Outperform
Becton, Dickinson and Company	Outperform Votes 601 62.41%	Underperform Votes 362 37.59%
Insulet	Outperform Votes 735 66.40%	Underperform Votes 372 33.60%

Do analysts rate BDX or PODD?

Becton, Dickinson and Company currently has a consensus price target of $278.29, indicating a potential upside of 21.47%. Insulet has a consensus price target of $292.06, indicating a potential upside of 6.58%. Given Becton, Dickinson and Company's stronger consensus rating and higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Insulet	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

Which has more risk & volatility, BDX or PODD?

Becton, Dickinson and Company has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in BDX or PODD?

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Insulet beats Becton, Dickinson and Company on 10 of the 18 factors compared between the two stocks.